MyChesCo on MSN41m
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily DosingDOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback